US Industry Earnings Intelligence

Biotechnology earnings map

Forward reporting exposure, estimate delivery, earnings growth and company-level event concentration.

Forward window13 Aug to 11 Nov 2026143 matched companies

Group read

The earnings tape is mixed beneath the calendar load

42% of companies with measured latest results beat estimates, while 100% show positive year-on-year EPS growth. Healthcare carries the largest forward market-cap exposure.

Forward events144next 90 days
Market-cap exposure$142.0Bmatched companies
Latest beat breadth42%latest measured quarter
Positive EPS growth100%year on year

Forward exposure

Biotechnology reporting load by date

Count and matched market cap

Delivery

Latest result breadth

42%beat breadth

Timing

Session certainty

72%estimate coverage

Growth breadth

Positive versus contracting

Company size

Capital at risk by tier

Company attention queue

Most consequential upcoming reports

Ordered by market capitalisation so the largest potential peer and index read-through appears first.

18 shown
ARGXargenx NV ADRBiotechnology
22 Oct70 days
Event risk38/100Moderate
Market cap$52.4BTime unconfirmed
Beat rate86%up to 8 quarters
EPS growth89.2%year on year
Open earnings dossier
SMMTSummit Therapeutics PLCBiotechnology
19 Oct67 days
Event risk38/100Moderate
Market cap$12.9BTime unconfirmed
Beat rate13%up to 8 quarters
EPS growth-year on year
Open earnings dossier
ABVXAbivax SA American Depositary SharesBiotechnology
14 Sep32 days
Event risk38/100Moderate
Market cap$10.6BTime unconfirmed
Beat rate50%up to 8 quarters
EPS growth-year on year
Open earnings dossier
CELCCelcuity LLCBiotechnology
13 Aug0 days
Event risk52/100Elevated
Market cap$6.4BTime unconfirmed
Beat rate63%up to 8 quarters
EPS growth-year on year
Open earnings dossier
BLTEBelite Bio Inc ADRBiotechnology
13 Aug0 days
Event risk47/100Elevated
Market cap$5.9BAfter the close
Beat rate13%up to 8 quarters
EPS growth-year on year
Open earnings dossier
CGONCG Oncology, Inc. Common stockBiotechnology
14 Aug1 days
Event risk51/100Elevated
Market cap$5.5BTime unconfirmed
Beat rate13%up to 8 quarters
EPS growth-year on year
Open earnings dossier
KLRAKailera Therapeutics, Inc. Common StockBiotechnology
25 Aug12 days
Event risk26/100Moderate
Market cap$3.1BTime unconfirmed
Beat rate0%up to 8 quarters
EPS growth-year on year
Open earnings dossier
NKTRNektar TherapeuticsBiotechnology
13 Aug0 days
Event risk55/100Elevated
Market cap$2.2BAfter the close
Beat rate63%up to 8 quarters
EPS growth-year on year
Open earnings dossier
NBTXNanobiotixBiotechnology
29 Sep47 days
Event risk43/100Moderate
Market cap$2.0BTime unconfirmed
Beat rate80%up to 8 quarters
EPS growth-year on year
Open earnings dossier
TYRATyra Biosciences IncBiotechnology
13 Aug0 days
Event risk44/100Moderate
Market cap$1.9BTime unconfirmed
Beat rate38%up to 8 quarters
EPS growth-year on year
Open earnings dossier
MESOMesoblast LtdBiotechnology
4 Sep22 days
Event risk49/100Elevated
Market cap$1.9BTime unconfirmed
Beat rate100%up to 8 quarters
EPS growth-year on year
Open earnings dossier
AAPGAscentage Pharma Group InternationalBiotechnology
19 Aug6 days
Event risk26/100Moderate
Market cap$1.9BBefore the open
Beat rate0%up to 8 quarters
EPS growth-year on year
Open earnings dossier
NRIXNurix Therapeutics IncBiotechnology
8 Oct56 days
Event risk32/100Moderate
Market cap$1.8BTime unconfirmed
Beat rate63%up to 8 quarters
EPS growth-year on year
Open earnings dossier
ATAIATAI Life Sciences BVBiotechnology
13 Aug0 days
Event risk60/100Elevated
Market cap$1.6BTime unconfirmed
Beat rate25%up to 8 quarters
EPS growth-year on year
Open earnings dossier
KALVKalvista Pharmaceuticals IncBiotechnology
13 Aug0 days
Event risk60/100Elevated
Market cap$1.4BTime unconfirmed
Beat rate38%up to 8 quarters
EPS growth-year on year
Open earnings dossier
OCSOculis Holding AG Ordinary sharesBiotechnology
20 Aug7 days
Event risk56/100Elevated
Market cap$1.4BTime unconfirmed
Beat rate25%up to 8 quarters
EPS growth-year on year
Open earnings dossier
COAGHemab Therapeutics Holdings, Inc. Common StockBiotechnology
20 Aug7 days
Event risk31/100Moderate
Market cap$1.4BTime unconfirmed
Beat rate-up to 8 quarters
EPS growth-year on year
Open earnings dossier
MPLTMapLight Therapeutics, Inc. Common StockBiotechnology
13 Aug0 days
Event risk60/100Elevated
Market cap$1.4BTime unconfirmed
Beat rate0%up to 8 quarters
EPS growth-year on year
Open earnings dossier

Forward company tape

Biotechnology upcoming earnings reports

120 shown

Interpretation

How to read group earnings intelligence

Calendar concentration

Counts show operational density. Market-cap exposure identifies dates with greater potential for peer and index read-through.

Delivery breadth

Only the latest measured result per matched company enters the breadth split, preventing long-history companies from dominating.

Growth breadth

Positive year-on-year EPS growth is kept separate from estimate surprise because growth and expectations answer different questions.

Decision use

The page helps prioritise research and event risk. It does not determine whether to buy, sell or expect a directional reaction.

Evidence context